Design
Review
Answers are grounded in this paper and cite their sources.
Supports heightened clinical vigilance for HCM; leaves open precise prevalence estimates from literature reviews alone.
Hypertrophic cardiomyopathy (HCM) is a disease characterized by primary hypertrophy of the left (and sometimes right) ventricle. The clinical manifestations of the disease are dyspnea, angina, and a continuum encompassing lightheadedness, presyncope, syncope, and sudden death. Although HCM is often caused by an identifiable mutation in a gene coding for a sarcomeric protein and inherited in an autosomal-dominant pattern, many patients do not have any relatives in whom the disease is manifest. The prevalence of HCM is estimated to be 0.2%, with nearly 600,000 Americans affected. This limited exposure of clinicians to HCM understandably accounts for the uncertainty that prevails regarding this disease and its management.
No takes yet. Share an insight, caveat, or question.
Radhakrishnan Ramaraj (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: